Indian pharmaceutical major Sun Pharmaceuticals posted 26% YoY profit growth in the March quarter. The Dilip Sanghvi-led company reported a consolidated net profit of Rs 2,714 crore in Q4 FY26. Its net profit in Q4 FY25 was at Rs 2,149 crore. Sequentially, Sun Pharma’s profit declined by 19%, with net profit in Q3 FY26 at Rs 3,368 crore. The company reported EBITDA of Rs 3,954 crore in Q4 FY26. Its EBITDA margins stood at 27% during the quarter. Further, Sun Pharma recorded 12.7% YoY revenue growth in the last quarter of FY26. Its consolidated revenue from operations grew to Rs 14,611 crore in Q4 FY26 from Rs 12,958 crore in the corresponding quarter last year. Sequentially, the revenue was down 5.8%.